I have been utilizing tumor organoid technology since 2020. Recently, I’ve come to appreciate how combining organoid technology with AI can revolutionize the drug discovery process by enhancing efficiency and accelerating personalized therapy development. Notably, using tumor organoid models to validate AI-driven antibody therapy data has further clarified their effectiveness, and the outcomes from my recent studies have exceeded expectations.